Video

Dr. Comerci on the Utility of Primary Debulking Surgery in Ovarian Cancer

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, UPMC Passavant Hospital, discusses the utility of primary debulking surgery in ovarian cancer.

In the last decade, the field has developed a greater understanding of which patients should receive upfront debulking surgery versus neoadjuvant chemotherapy, says Comerci. Elderly patients are not typically eligible for primary debulking surgery due to their age, performance status, and comorbidities, says Comerci.

Physical activity may influence surgical eligibility, says Comerci. For example, an 80-year-old patient who is physically active may be able to tolerate the stress of surgery.

Additionally, laparoscopic imaging has made it easier to determine primary debulking surgical eligibility, concludes Comerc

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD